SCHEMBL12371023

SCHEMBL12371023

O=C1CC(C2CCC(c3ccc(-c4ccc(OC(F)(F)F)cc4)cc3)CC2)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
GRM2 Q14416 2/20 0.40
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
WNT3A P56704 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
NOTUM Q6P988 1/20 0.36
SCN5A Q14524 3/20 0.36
TEAD1 P28347 2/20 0.36
P2RY14 Q15391 1/20 0.36
PRKDC P78527 1/20 0.36
KIF11 P52732 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371006 0.96 L3MBTL1 (0.43) L3MBTL1GRM2MEN1KMT2AWNT3A
SCHEMBL12370946 0.95 L3MBTL1 (0.43) L3MBTL1GRM2MEN1KMT2AWNT3A
SCHEMBL12371032 0.80 NOTUM (0.38) NOTUMTEAD1
SCHEMBL8767160 0.79 L3MBTL1 (0.44) L3MBTL1MEN1KMT2AP2RY14KIF11
SCHEMBL8767158 0.79 L3MBTL1 (0.44) L3MBTL1MEN1KMT2AP2RY14KIF11
SCHEMBL12371016 0.79 TNKS (0.37) MEN1KMT2ATNKS2NOTUMTUBB4A
SCHEMBL12395782 0.78 ESR2 (0.47)
SCHEMBL12371048 0.78 ALDH1A1 (0.44) MEN1KMT2A
SCHEMBL12371002 0.78 EPHX2 (0.36) EPHX2
SCHEMBL12371028 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2020407-B1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF JNC CORP (JP) 2013-07-03 EP disclosed
US-7999123-B2 2-oxetanone derivative and process for production thereof JNC CORPORATION (JP) 2011-08-16 US disclosed
US-7999123-B2 2-oxetanone derivative and process for production thereof JNC CORPORATION (JP) 2011-08-16 US disclosed
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2009-11-05 US disclosed
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2009-11-05 US disclosed
EP-2020407-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF Chisso Corporation (JP) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF OGDH, OXGR1, OXER1 L3MBTL1 3749/4885GRM2 1003/4885MEN1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.